Global Dry Eye Disease Drug Pipeline Research Report 2022: Comprehensive Insights About 50+ Companies and 50+ Pipeline Drugs - ResearchAndMarkets.com

This "Dry Eye Disease- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, May 25, 2022
Information
Tags: 
Health, Pharmaceutical, Inflammation, Uveitis, II, Duane syndrome, News, Patient, Plastoquinone, RASP, ROS, Mergers and acquisitions, Reactive oxygen species, Clinical trial, Neurotrophic keratitis, Dry eye syndrome, III, Technology, Apoptosis, NDA, Therapy, Discovery, Mitochondrion, Acquisition, Cornea, Veterinary medicine, Pharmaceutical industry, Poultry
Summary
Key Points: 
  • This "Dry Eye Disease- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape.
  • A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines.
  • The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D.


The "Dry Eye Disease - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Dry Eye Disease- Pipeline Insight, 2022" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Dry Eye Disease pipeline landscape is provided which includes the disease overview and Dry Eye Disease treatment guidelines. The assessment part of the report embraces, in depth Dry Eye Disease commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Eye Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

The companies and academics are working to assess challenges and seek opportunities that could influence Dry Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve Dry Eye Disease.

Dry Eye Disease Emerging Drugs Chapters

This segment of the Dry Eye Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dry Eye Disease Emerging Drugs

Reproxalap: Aldeyra Therapeutics

Reproxalap, is a novel small molecule drug candidate for Dry Eye. By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. In a Phase II b clinical trial, Aldeyra's lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.

Timbetasin: RegeneRx Biopharmaceuticals

RGN-259, a T?4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that T?4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.

Visomitin: Mitotech

Visomitin, contains a novel small molecule cardiolipin peroxidation inhibitor, specifically developed to target ophthalmic disorders such as dry eye syndrome, uveitis and age-related macular degeneration, in an eye drop formulation for ease of administration. Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

Dry Eye Disease: Therapeutic Assessment

This segment of the report provides insights about the different Dry Eye Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dry Eye Disease

There are approx. 50+ key companies which are developing the therapies for Dry Eye Disease. The companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, RegeneRx Biopharmaceuticals.

Dry Eye Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dry Eye Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Eye Disease drugs.

Key Questions Answered

  • How many companies are developing Dry Eye Disease drugs?
  • How many Dry Eye Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Eye Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dry Eye Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dry Eye Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • TearSolutions
  • HanAll Biopharma
  • Aldeyra Therapeutics
  • RegeneRx Biopharmaceuticals
  • Mitotech
  • Novaliq
  • Oyster Point Pharma
  • Aerie Pharmaceuticals
  • Azura Ophthalmics
  • Stuart Therapeutics
  • Surface Ophthalmics
  • Glaukos Corporation

Key Products

  • Reproxalap
  • Timbetasin
  • Visomitin
  • NOV03
  • HL036
  • OC-01
  • CyclASol
  • Lacripep
  • HBM9036
  • AR15512
  • AZR MD 001
  • ST-100
  • SURF-100
  • SURF-200
  • GLK-301

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/fglhp1

Copyright: 
Copyright Business Wire 2022